Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1901 - Utility of p16 over-expression in squamous cell carcinoma cervix with pulmonary metastasis (295P)


18 Nov 2017


Poster lunch


Chandan Das


Annals of Oncology (2017) 28 (suppl_10): x86-x93. 10.1093/annonc/mdx663


C.K. Das, H. Walia

Author affiliations

  • Medical Oncology, Ivy Hospital, 160071 - Mohali/IN


Abstract 1901


Cervical cancer is one of the most common cancer in women worldwide, and developing countries accounts for approximately 80% of cases occur. Pulmonary metastasis was reported to occur in 3.1% to 8.2% of patients with cervical carcinoma. Human Papilloma Virus (HPV) induced carcinogenesis signatures can be detected in more than 95% of cases. Overexpression of p16 as a surrogate marker well established in various HPV-related malignancies. As lung is the most common distant metastatic site in carcinoma cervix, distinguishing it from primary pulmonary malignancies is paramount importance in management. This study evaluates the diagnostic potential of p16 in the evaluation of pulmonary metastasis from cervix cancer.


Formalin-fixed, paraffin-embedded biopsy specimens of primary cervix cancer(n = 68), the primary squamous cell ca lung (n = 32) and pulmonary metastasis from the cervix (n = 22) analysed using automated Ventana immunohistochemical platform (Ventana Medical Systems, Tucson, AZ). Nuclear or cytoplasmic p16 staining score calculated as follows: negative for fewer than 10%; positive for >10% reactive.


Overexpression of p16 seen in 65/68 [95.5%] primary cervical biopsies Only two cases of primary squamous cell carcinoma lung showed p16 reactivity. Among the cases of metastatic cervix carcinoma to lung 18/22 (81.8) are positive for p16 immunoreactivity.Table: 295P

p16 immunoexpression in various tissue type

Tissue of originP16 10% Positive
Primary Squamous cell carcinoma cervix (n = 68)365
Primary squamous cell carcimona lung (n = 32)302
Pulmonary metastasis from cervical squamous cell carcinoma (n = 22)418


This study evaluated the usefulness of p16 immunoreactivity in pulmonary metastasis evaluation. The HPV-driven carcinogenesis pathway of cervix cancer preserved even at the metastatic site. With a cut-off of 10% the sensitivity and specificity of p16 is 81.82% and 93.75% respectively.

Clinical trial identification

Not Applicable

Legal entity responsible for the study

Chandan Krushna Das




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings